

# References

## Chapter 18

- 1 Stated by Dr Barry Bloom, dean of Harvard School of Public Health. Referred to in Johnson JA, Stoskopf C. *Comparative Health Systems: Global Perspectives*. Burlington, MA, Jones & Bartlett, 2010.
- 2 World Health Organization. *Monitoring the Building Blocks of Health Systems: A Handbook of Indicators and Their Measurement Strategies*. Geneva, World Health Organization, 2010.
- 3 World Health Organization. *The World Health Report 2000 – Health Systems: Improving Performance*. Geneva, World Health Organization, 2000.
- 4 Goodwin N. National health systems: overview. In: van de Beek D, de Gans J, eds. *International Encyclopedia of Public Health*. Amsterdam, Elsevier, 2008: 497–512.
- 5 Egger D, Ollier E. Managing the Health Millennium Development Goals – The Challenge of Management Strengthening: Lessons from Three Countries. *Making Health Systems Work: Working Paper No. 8 WHO/HSS/Healthsystems/2007.1*. Geneva, Department for Health Policy, Development and Services Health Systems and Services WHO, 2007.
- 6 Marmor T, Wendt C. Conceptual frameworks for comparing healthcare politics and policy. *Health Policy*. 2012;**107**(1):11–20.
- 7 Wendt C, Frisina L, Rothgang H. Healthcare system types: a conceptual framework for comparison. *Social Policy & Administration*, 2009;**43**:70–90.
- 8 Stevens FCJ, van der Zee J. Health system organization models (including targets and goals for health systems). In: Kirch W, ed. *Encyclopedia of Public Health Editors*. Rotterdam, Springer, 2008: 247–56.
- 9 Herrera CA, Rada G, Kuhn-Barrientos L, Barrios X. Does ownership matter? An overview of systematic reviews of the performance of private for-profit, private not-for-profit and public healthcare providers. *PLoS ONE*. 2014;**9**(12):e93456.
- 10 Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. *Health Affairs (Project Hope)*. 2008;**27**:759–69.
- 11 Shakarishvili G, Lansang MA, Mitta V, Bornemisza O, Blakley M, Kley N, Burgess C, Atun R. Health systems strengthening: a common classification and framework for investment analysis. *Health Policy Plan*. 2011;**26**(4):316–26.
- 12 Thorpe KE. The rise in health care spending and what to do about it. *Health Affairs*. 2005;**24**:1436–45.
- 13 Organisation for Economic Co-operation and Development. *Health at a Glance 2011: OECD Indicators. Pharmaceutical expenditure*. OECD Publishing. Available from: <http://www.oecd.org/els/health-systems/49105858.pdf> (last accessed 18 November 2015).
- 14 Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. *Lancet*. 2009;**373**:240–9.
- 15 Wagner AK, Graves AJ, Reiss SK, Lecates R, Zhang F, Ross-Degnan D. Access to care and medicines, burden of health care expenditures, and risk protection: results from the World Health Survey. *Health Policy*. 2011;**100**:151–8.
- 16 Bigdeli M, Peters DH, Wagner AK. *Medicines in Health Systems: Advancing Access, Affordability and Appropriate Use*. Geneva, World Health Organization, 2014.
- 17 Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrado S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. *Frontiers in Pharmacology*. 2014;**5**:106.
- 18 Wettermark B, Jacobsson B, Godman B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical

- polycymaking – an overview of current approaches and their consequences. *Applied Health Economics and Health Policy*. 2009;**7**:1–11
- 19 Barber SL, Huang B, Santoso B, Laing R, Paris V, Wu C. The reform of the essential medicines system in China: a comprehensive approach to universal coverage. *Journal of Global Health*. 2013;**3**(1):010303.
- 20 Wagstaff A. Health systems in East Asia: what can developing countries learn from Japan and the Asian Tigers? *Health Economics*. 2007;**16**(5):441–56.
- 21 Laing R, Waning B, Gray A, Ford N, 't Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. *Lancet*. 2003;**361**(9370):1723–9.
- 22 Morden NE, Sullivan SD. States' control of prescription drug spending: a heterogeneous approach. *Health Affairs*. 2005;**24**(4):1032–8.
- 23 WHO 2010. Key components of a well functioning health system. Available from: [http://www.who.int/healthsystems/EN\\_HSSkeycomponents.pdf](http://www.who.int/healthsystems/EN_HSSkeycomponents.pdf) (last assessed 18 November 2015).
- 24 Lawn J, Rohde J, Rifkin S, Were M, Paul VK, Chopra M. Alma-Ata: rebirth and revision 1. Alma-Ata 30 years on: revolutionary, relevant, and time to revitalize. *Lancet*. 2008;**372**:917–27.
- 25 Holloway KA, Henry D. WHO essential medicines policies and use in developing and transitional countries: an analysis of reported policy implementation and medicines use surveys. *PLoS Medicine*. 2014;**11**:e1001724.
- 26 Brennan T, Shrank W. New expensive treatments for hepatitis C infection. *Journal of the American Medical Association*. 2014;**312**:593–4.
- 27 Kaplan W, Wirtz V, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. Priority Medicines for Europe and the World 2013 Update Report. Available from: [http://www.who.int/medicines/areas/priority\\_medicines/MasterDocJune28\\_FINAL\\_Web.pdf?ua](http://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_Web.pdf?ua) (last accessed 18 November 2015).
- 28 Lobato LVC, Giovanella L. Sistemas de Saúde: origens componentes dinâmica. In: Govanella L, Escorel S, Lobato LVC, et al., eds. *Políticas e Sistemas de Saúde no Brasil*. Rio de Janeiro, Fiocruz, 2008: 107–39.
- 29 Nuwer MR. Public policy and healthcare systems. *Handbook of Clinical Neurology*. 2013;**118**:277–87.
- 30 Remme JH, Adam T, Becerra-Posada F, D'Arcangues C, Devlin M, Gardner C, et al. Defining research to improve health systems. *PLoS Medicine*. 2010;**7**(11):e1001000.
- 31 Seiter A. A Practical Approach to Pharmaceutical Policy. Washington, DC, World Bank, 2010. Available from: [http://www-wds.worldbank.org/external/default/WDSContentServer/IW3P/IB/2010/06/22/000334955\\_20100622050742/Rendered/PDF/552030PUB0Phar10Box349442B01PUBLIC1.pdf](http://www-wds.worldbank.org/external/default/WDSContentServer/IW3P/IB/2010/06/22/000334955_20100622050742/Rendered/PDF/552030PUB0Phar10Box349442B01PUBLIC1.pdf) (last accessed 18 November 2015).
- 32 Daemmrch A, Mohanty A. Healthcare reform in the United States and China: pharmaceutical market implications. *Journal of Pharmaceutical Policy Practice*. 2014;**7**(1):9.
- 33 Mansfield SJ. Generic drug prices and policy in Australia: room for improvement? A comparative analysis with England. *Australian Health Review*. 2014;**38**(1):6–15.
- 34 Dylst P, Simoens S. Does the market share of generic medicines influence the price level?: a European analysis. *Pharmacoeconomics*. 2011;**29**:875–82.
- 35 Perriëns JH, Habiyambere V, Dongmo-Nguimfack B, Hirnschall G. Prices paid for adult and paediatric antiretroviral treatment by low- and middle-income countries in 2012: high, low or just right? *Antiviral Therapy*. 2014;**19**(Suppl. 3):39–47.
- 36 Pauwels K, Huys I, Casteels M, Simoens S. Drug shortages in European countries: a trade-off between market attractiveness and cost containment? *BMC Health Services Research*. 2014;**14**:438.
- 37 Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory review of novel therapeutics – comparison of three regulatory agencies. *New England Journal of Medicine*. 2012;**366**(24):2284–93.
- 38 Packer C, Simpson S, Stevens A; EuroScan: the European Information Network on New and Changing Health Technologies. International diffusion of new health technologies: a ten-country analysis of six health technologies. *International Journal of Technology Assessment in Health Care*. 2006;**22**:419–28
- 39 Stolk P, Heemstra HE, Leufkens HG, Bloechl-Daum B, Heerdink ER. No difference in between-country variability in use of newly approved orphan and non-orphan medicinal products – a pilot study. *Orphanet Journal of Rare Diseases*. 2009;**4**:27.
- 40 Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A; Working Group 'Equity

- in Access to Treatment of Rheumatoid Arthritis in Europe'. Inequities in access to biologic and synthetic DMARDs across 46 European countries. *Annals of the Rheumatic Diseases*. 2014;**73**:198–206.
- 41 Bae G, Bae EY, Bae S. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea. *Health Policy*. 2015. pii: S0168-8510(15)00027-5.
- 42 Srivastava D, McGuire A. Analysis of prices paid by low-income countries – how price sensitive is government demand for medicines? *BMC Public Health*. 2014;**14**:767.
- 43 Masters SH, Burstein R, DeCenso B, Moore K, Haakenstad A, Ikilezi G, et al. Pharmaceutical availability across levels of care: evidence from facility surveys in Ghana, Kenya, and Uganda. *PLoS ONE*. 2014;**9**(12):e114762.
- 44 Mäkinen M, Rautava P, Forsström J, Aärimala M. Electronic prescriptions are slowly spreading in the European Union. *Telemed Journal of European Health*. 2011;**17**(3):217–22.
- 45 Luffman J. Out-of-pocket spending on prescription drugs. *Statistics Canada*. Catalogue no. 75-001-XIE, 2005.
- 46 Niëns LM, Cameron A, Van de Poel E, Ewen M, Brouwer WB, Laing R. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. *PLoS Medicine*. 2010;**7**(8):e1000333.
- 47 Wettermark B, Vlahovic-Palcevski V, Laing R, Bergman U. Adherence to WHO's Essential Medicines List in two European countries. *WHO Drug Information*. 2006;**20**:78–85.
- 48 Carlsen B, Kjellberg PK. Guidelines; from foe to friend? Comparative interviews with GPs in Norway and Denmark. *BMC Health Services Research*. 2010;**10**:17.
- 49 Stolk P, Van Wijk BL, Leufkens HG, Heerdink ER. Between-country variation in the utilization of anti-hypertensive agents: guidelines and clinical practice. *Journal of Human Hypertension*. 2006;**20**(12):917–22.
- 50 McKinlay J, Link C, Marceau L, O'Donnell A, Arber S, Adams A, Lutfey K. How do doctors in different countries manage the same patient? Results of a factorial experiment. *Health Services Research*. 2006;**41**(6):2182–200.
- 51 Grigoryan L, Burgerhof JG, Degener JE, Deschepper R, Lundborg CS, Monnet DL, et al.; SAR Consortium. Attitudes, beliefs and knowledge concerning antibiotic use and self-medication: a comparative European study. *Pharmacoepidemiology and Drug Safety*. 2007;**16**:1234–43.
- 52 Grigoryan L, Burgerhof JG, Degener JE, Deschepper R, Lundborg CS, Monnet DL, et al.; Self-Medication with Antibiotics and Resistance (SAR) Consortium. Determinants of self-medication with antibiotics in Europe: the impact of beliefs, country wealth and the healthcare system. *Journal of Antimicrobial Chemotherapy*. 2008;**61**:1172–9.
- 53 Haak H, Hardon AP. Indigenised pharmaceuticals in developing countries: widely used, widely neglected. *Lancet*. 1988;**2**:620–1.
- 54 Wessling A. Over-the-counter sales of drugs in Sweden 1976–1983. *European Journal of Clinical Pharmacology*. 1987;**33**:1–6.
- 55 Moen J, Antonov K, Larsson CA, Lindblad U, Nilsson JL, Råstam L, Ring L. Factors associated with multiple medication use in different age groups. *Annals of Pharmacotherapy*. 2009;**43**:1978–85.
- 56 Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. *Journal of the American Medical Association*. 2008;**300**:2867–78.
- 57 Walker R, Hinchliffe A. Prescribing and sale of ophthalmic chloramphenicol following reclassification to over-the-counter availability. *International Journal of Pharmacy Practice*. 2010;**18**:269–74.
- 58 von Euler M, Keshani S, Baatz K, Wettermark B. Utilization of triptanes in Sweden; analyses of over the counter and prescriptions sales. *Pharmacoepidemiology and Drug Safety*. 2014;**23**:1288–93.
- 59 Andrade SE, Gurwitz JH, Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. *Medical Care*. 1999;**37**:424–30.
- 60 Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. *American Journal of Managed Care*. 2005;**11**:374–82.
- 61 Filion KB, Delaney JA, Brophy JM, Ernst P, Suissa S. The impact of over-the-counter simvastatin on the

- number of statin prescriptions in the United Kingdom: a view from the General Practice Research Database. *Pharmacoepidemiology and Drug Safety*. 2007;**16**:1–4.
- 62** Gauld NJ, Kelly FS, Kurosawa N, Bryant LJ, Emmerton LM, Buetow SA. Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison. *PLoS ONE*. 2014;**9**(9):e107726.
- 63** Ernst E. Prevalence of use of complementary/alternative medicine: a systematic review. *Bulletin of the World Health Organization*. 2000;**78**:252–7.
- 64** Ni H, Simile C, Hardy AM. Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey. *Medical Care*. 2002;**40**:353–8.
- 65** Klepser TB, Doucette WR, Horton MR, Buys LM, Ernst ME, Ford JK, et al. Assessment of patients' perceptions and beliefs regarding herbal therapies. *Pharmacotherapy*. 2000;**20**:83–7.
- 66** Stange R, Amhof R, Moebus S. Complementary and alternative medicine: attitudes and patterns of use by German physicians in a national survey. *Journal of Alternative and Complementary Medicine*. 2008;**14**:1255–61.